BOCA RATON, FL--(Marketwire - September 14, 2010) - David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that the Company has named Christopher Vissman National Sales Manager, a new position. Mr. Vissman will be working from Nashville, TN, and Boca Raton, FL. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events including cardiac death resulting from arrhythmia or pump failure, and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.
"We are extremely fortunate and gratified to have Chris join Vicor as our National Sales Manager. Chris has more than 20 years of sales management experience, with the last 10 of these -- most importantly to Vicor -- focused on our market niche. We are confident that having Chris leading our national sales effort will ensure successful roll-out and reception of our PD2i Analyzer™," stated Mr. Fater.
Concurrent with Mr. Vissman's hire, Vicor has contracted with 10 independent sales representatives to cover multiple territories, including New England, Annapolis/DC, Atlanta, Dallas, Manhattan, Boston, Las Vegas, Denver, Knoxville, and Tucson.
Mr. Vissman is an accomplished sales executive with more than 20 years of building sales teams, creating winning sales strategies, and managing multiple sales channels. Most recently, he was a Principal of Medical Technologies, LLC, responsible for the hiring, training, and management of a national sales team introducing new technologies to primary care physicians, cardiologists, and endocrinologists. Prior to that, he was President of Innovative Diagnostics, Inc., start-up creator of a cardiac autonomic neuropathy diagnostic, for which Mr. Vissman developed a 40-person independent sales team, marketing materials, sales processes and programs, and successfully negotiated a national GPO contract. Earlier, Mr. Vissman was the National Sales Training Manager for CardioDynamics. During his tenure, he re-designed the Company's new hire sales training program, which led to a 71% improvement in first month sales and 29% improvement in first quarter sales, and developed an advanced sales training program for representatives with between one and two years of experience, incorporating principles and practices of representatives consistently ranked in the top 20%. Before that, Mr. Vissman was District Manager for Polymedco, Inc., where he ranked among the top five sales representatives (among 40-45) in monthly new business closes in all categories. Earlier, Mr. Vissman held senior positions with non-medical industry companies, including Vice President of Sales & Marketing at Global Aqua Solutions; Territory Manager for Sika Corp., and District Sales Manager for Lochinvar Corp. Mr. Vissman holds a BA in Industrial Marketing and General Business from Western Michigan University.
The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense, the U.S. Government, or the AABB of the information, products or services contained therein.
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a claim for the PD2i CA™ (Cardiac Analyzer) for risk stratifying congestive heart failure patients at elevated risk of cardiac mortality and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.